FLASH NEWS LIVE

Intellia Therapeutics Q4 Earnings Call Highlights

Intellia Therapeutics Q4 Earnings Call Highlights

Intellia Therapeutics (NASDAQ:NTLA) management used its fourth-quarter and full-year 2025 earnings call to highlight progress across its two lead in vivo CRISPR gene-editing programs—lonvo-z in hereditary angioedema (HAE) and Nex-z in transthyretin (TTR) amyloidosis—while providing updates on the regulatory status of its ATTR clinical trials and outlining commercial preparation for a potential HAE launch. Company [...]

Read Full Article →

📱 Tip: Tap the 🔗 Share icon in Safari and choose Add to Home Screen to install World Trade Factory.
Instagram Meta X LinkedIn Whatsapp